Another patent titled Enantiomers of 8-Hydroxy Quinoline derivatives and the synthesis on the synthesis and application of the enantiopure candidates, including Q134R was submitted in 2015 (patent application number: WO2016162706 A1), and is under granting process in U.S.A., Europe, Canada, Eurasia, Australia, China, Indonesia, Japan, South-Korea, Mexico, New-Zealand, Brazil, and India.

Summary: The novel medicinal and/or pharmaceutical compositions empowers these enantiomers to be used preferably as cytoprotective, neuroprotective, cardioprotective, anxiolytic and antidepressant agents for the treatment of neuropsychiatric and neurologic diseases and diseases in connections with transplantations and with ischemia and reperfusion injuries, further the inhibition of organ and skin graft rejection. According to our studies the R-enantiomer has either sole or high biological effect in some cases.